Supply Chain & Operational Scale
Biopharma Supply Chain and Operational Scale Advisory
A strong pipeline without a scalable supply chain is a company that cannot deliver on its promises. Biopharma supply chains are among the most complex and regulated in any industry — and the decisions made about manufacturing partners, quality systems, and operational infrastructure in the early stages of a company's development have consequences that compound for years.
At Katogen, we help biopharma companies build the supply chain and operational infrastructure they need to support growth — drawing on 35+ years of hands-on experience building, scaling, and turning around biopharma operations across multiple therapeutic areas and modalities.
What We Do
Supply Chain Strategy and Design We help companies build supply chain strategies that are scalable, resilient, and aligned with their commercial and regulatory requirements — from raw material sourcing through finished product distribution.
CDMO Selection and Partnership Management Selecting the right contract development and manufacturing organization is one of the most consequential decisions a biopharma company makes. We help companies develop CDMO selection criteria, run rigorous selection processes, and negotiate contracts that protect their interests across the full development and commercialization lifecycle.
Quality Systems and Regulatory Readiness A quality system that cannot withstand FDA inspection is a liability, not an asset. We help companies build quality management systems that are both operationally effective and inspection-ready — and that will survive the scrutiny of a sophisticated acquirer's diligence team.
Operational Scalability Planning Can your supply chain handle 3x volume? 10x? We help companies stress-test their operational infrastructure against realistic growth scenarios — and build the roadmap to close the gaps before they become constraints.
Supply Chain Risk Management Single-source dependencies, geopolitical risk, API supply concentration — we help companies identify and mitigate the supply chain risks that are most likely to disrupt their business and most likely to be flagged in diligence.
Who This Is For
CEOs and COOs at growth-stage and mid-sized biopharma companies building or scaling their operational infrastructure — particularly those preparing for a launch, a significant volume increase, a regulatory inspection, or a potential transaction.
Why Katogen
We have built and scaled biopharma supply chains across multiple companies, modalities, and geographies. We understand the operational decisions that create long-term competitive advantage — and the ones that create long-term risk.